PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities. Intellectual Property Patents The company has been issued patents in the United States and elsewhere, covering the humanization of antibodies, which are referred to as its Queen et al. patents.The company was founded as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.
Current Team (3)Update
|Aug 30, 2016||google.com - PDL BioPharma Inc|
|Sep 28, 2015||genengnews.com - PDL BioPharma Buys Portion of Zalviso™ Royalties, Milestones for $65M|
|Jul 14, 2015||Xconomy - Celgene to Acquire San Diego's Receptos for $7.2B in Cash|
|May 18, 2015||Business Wire - Allergen Research Corporation Names Mark McDade as Chairman and Mark Iwicki as Member of the Board of Directors|
|Jan 5, 2015||Fierce Medical Devices - Med techs Avinger, HTG file for IPOs|
|Nov 18, 2014||PRNewswire All - PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics|
|Nov 6, 2014||PRNewswire All - PDL BioPharma Acquires a Portion of the University of Michigan's Royalty Interest in Genzyme's Cerdelga™ (eliglustat) Capsules for $65.6 Million|
|Feb 3, 2010||Xconomy - Google Pours “Incredible” Computing Power into Antibody Drug Discovery With Adimab|
932 Southwood Blvd.
Incline Village, NV 89451